Neurosearch skyrockets on positive Phase III Huntington's results
04 February 2010
Asher Mullard
Please Login to read the full article.
04 February 2010
Asher Mullard
Neurosearch's novel therapy Huntexil (pridopidine) met its primary endpoint, improving motor function in a Phase III Huntington's study, show top-line results. Excited investors drove the share price up by over 100% to close at 168.00 Danish crowns ($31.55) on February 3rd on the Copenhagen...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
